

SETTING OF AN OBSERVATORY OF CLINICAL TRIAL DATA SHARING, RESEARCH INTEGRITY AND JOURNAL EDITORS

Karmela Krleža-Jerić¹, Mario Malički¹, Ludovic Reveiz², Ana Marušić¹

¹Department of Research in Biomedicine and Health, University of Split School of Medicine, Split, Croatia

²Department of Health Systems and Services, Pan American Health Organization, Washington DC, United States of America

BACKGROUND

IMPACT (**IMP**rove **A**ccess to **C**linical **T**rial data)
Observatory was established in October 2014 in Split,
Croatia, with the aim of monitoring the transition of clinical research regarding transparency of trial data.¹

The methodology of the Observatory includes scoping reviews of literature, surveys, interviews, and assessments of relevant initiatives and repositories.

By repeating a survey conducted in 2009 on WAME members,² the Observatory is attempting to determine the changes of perception, policies and practices of editors regarding various levels of public disclosure of patient-oriented research data.

METHODS

An anonymous and voluntary questionnaire was sent using the SurveyMonkey platform to all registered WAME members (n=1632) on 13 August 2015, with two reminders sent in September. The survey consisted of 38 questions.


Response rate till 18 September was 85 (5%). Sociodemographic characteristics of respondents are shown in Table 1. Most respondents journals are full open access journals (n=65, 77%), and not indexed in PubMed (n=44,52%).

Table 1. Sociodemographic characteristics of WAME members (n=85).


11101110013 (11–00).	
Characteristic	Mean ± SD
Age (years)	48 ± 13
Sex	n (%)
Male	15 (18)
Female	69 (82)
Position	n (%)
Editor in Chief	55 (65)
Associate Editor	9 (11)
Other (Deputy/Managing/Section editor)	21 (24)

RESULTS

Does your journal require clinical trials to be registered in an ICMJE- or WHO-approved trial register?



How would you characterize your journal's current position on sharing raw data from patient-oriented research including clinical trials?



Are you aware of any initiatives that encourage the publication and sharing of participant-level data?

No, 82% Yes, 18%

Table 2. Respondents' (n=65) personal opinion on which aspects of clinical trials should be publicly available?

Opinion	n (%)
None	2 (3)
Summary of trial protocol	33 (51)
Full protocol	36 (55)
Summary of results	37 (57)
All results	30 (46)
Individual (de-identified/anonymized) participant data - raw data	20 (31)
Statistical code	22 (34)
Clinical Study Report (if it exists)	28 (44)
All trial documentation (including consent forms and all data collection instruments)	22 (34)
Full financial disclosure of the research	41 (63)

CONCLUSION

- ➤ Initial results indicate that many journals still do not require registration of clinical trials before their publication, nor do they require authors to publicly share raw data. Additionally, despite the recent increase of data sharing initiatives, the large majority of editors are unaware of their existence.
- As our current response rate is only 5%, we refrain from making direct comparison with the results from 2009 study and generalizing our findings until we obtain more responses.
- Nevertheless, the high reported unawareness of data sharing initiatives coupled with the fact than more than two thirds of editors disagreed that raw data should be made publicly available, indicate a need for a greater dialog between stakeholders involved in data sharing.

ACKNOWLEDGMENTS

Karmela Krleža-Jerić was awarded a NEWFELPRO Fellowship (Marie Sklodowska Curie and Croatian Government Grant) to set up the IMPACT observatory. Ana Marušić is the chair of WAME Research Committee.

REFERENCES

- 1) Krleža-Jerić K, IMPACT. Available at: http://ottawagroup.ohri.ca/disclosure.htm
- 2) Krleža-Jerić K, Sim I, Marušić A, Reveiz L. Granados C. Medical Journal Editor Perspectives on Sharing Results Data From Patient-Oriented Research: A WAME Survey. 6th International Congress on Peer Review and Biomedical Publications, Vancouver, Sept 10-12, 2009.

CONTACT

Karmela Krleza-Jeric, MD. M.Sc., D.Sc.
Department of Research in Biomedicine and Health,
University of Split School of Medicine
Šoltanska 2, 21000 Split, Croatia
karmela.krleza-jeric@mefst.hr